| RS2481401336 |
NEU1
|
Health Risk |
Likely pathogenic |
— |
| RS2481402996 |
NEU1
|
Health Risk |
Pathogenic |
— |
| RS2481403672 |
NEU1
|
Health Risk |
Pathogenic |
— |
| RS2481407914 |
NEU1
|
Health Risk |
Likely pathogenic |
— |
| RS2481408384 |
NEU1
|
Health Risk |
Pathogenic |
— |
| RS2481409372 |
NEU1
|
Health Risk |
Pathogenic |
— |
| RS2481410901 |
LMBRD1
|
Health Risk |
Likely pathogenic |
Methylmalonic aciduria and homocystinuria type cblF, Methylmalonic aciduria and homocystinuria type cblF |
| RS2481411360 |
LMBRD1
|
Health Risk |
Pathogenic |
Methylmalonic aciduria and homocystinuria type cblF, Methylmalonic aciduria and homocystinuria type cblF |
| RS2481411386 |
LMBRD1
|
Health Risk |
Likely pathogenic |
Methylmalonic aciduria and homocystinuria type cblF, Methylmalonic aciduria and homocystinuria type cblF |
| RS2481414438 |
NEU1
|
Health Risk |
Pathogenic |
— |
| RS2481466290 |
LMBRD1
|
Health Risk |
Likely pathogenic |
Methylmalonic aciduria and homocystinuria type cblF, Methylmalonic aciduria and homocystinuria type cblF |
| RS2481466497 |
LMBRD1
|
Health Risk |
Pathogenic |
Methylmalonic aciduria and homocystinuria type cblF, Methylmalonic aciduria and homocystinuria type cblF |
| RS2481485775 |
LMBRD1
|
Health Risk |
Pathogenic |
Methylmalonic aciduria and homocystinuria type cblF, Methylmalonic aciduria and homocystinuria type cblF |
| RS2481498586 |
IMPG1
|
Health Risk |
Likely pathogenic |
— |
| RS2481499681 |
LMBRD1
|
Health Risk |
Likely pathogenic |
Methylmalonic aciduria and homocystinuria type cblF, Methylmalonic aciduria and homocystinuria type cblF |
| RS2481526979 |
IMPG1
|
Health Risk |
Likely pathogenic |
Retinal dystrophy, Retinal dystrophy |
| RS2481539365 |
IMPG1
|
Health Risk |
Likely pathogenic |
— |
| RS2481557966 |
BCKDHB
|
Health Risk |
Pathogenic |
Maple syrup urine disease, Maple syrup urine disease |
| RS2481558517 |
BCKDHB
|
Health Risk |
Likely pathogenic |
Maple syrup urine disease, Maple syrup urine disease |
| RS2481558879 |
BCKDHB
|
Health Risk |
Pathogenic |
Maple syrup urine disease, Maple syrup urine disease |
| RS2481559149 |
BCKDHB
|
Health Risk |
Likely pathogenic |
Maple syrup urine disease, Maple syrup urine disease |
| RS2481559722 |
BCKDHB
|
Health Risk |
Likely pathogenic |
Maple syrup urine disease, Maple syrup urine disease type 1B |
| RS2481564750 |
KCNQ5
|
Health Risk |
Pathogenic |
— |
| RS2481566230 |
KCNQ5
|
Health Risk |
Pathogenic |
— |
| RS2481567115 |
UMPS
|
Health Risk |
Pathogenic |
Cardiomyopathy, Oroticaciduria |
| RS2481569360 |
KCNQ5
|
Health Risk |
Likely pathogenic |
Intellectual disability, autosomal dominant 46 |
| RS2481575908 |
BCKDHB
|
Health Risk |
Likely pathogenic |
Maple syrup urine disease, Maple syrup urine disease |
| RS2481576688 |
BCKDHB
|
Health Risk |
Likely pathogenic |
Maple syrup urine disease, Maple syrup urine disease |
| RS2481589248 |
IMPG1
|
Health Risk |
Pathogenic |
— |
| RS2481606711 |
HFE
|
Health Risk |
Pathogenic |
Hereditary hemochromatosis, Hereditary hemochromatosis |
| RS2481619371 |
HFE
|
Health Risk |
Pathogenic |
Hereditary hemochromatosis, Hereditary hemochromatosis |
| RS2481620137 |
HFE
|
Health Risk |
Pathogenic |
Hereditary hemochromatosis, Hereditary hemochromatosis |
| RS2481621832 |
HFE
|
Health Risk |
Pathogenic |
Hereditary hemochromatosis, Hereditary hemochromatosis |
| RS2481623573 |
EHMT2
|
Health Risk |
Pathogenic |
Kleefstra-like syndrome, Kleefstra-like syndrome |
| RS2481647144 |
MLIP
|
Health Risk |
Pathogenic |
Myopathy with myalgia, increased serum creatine kinase |
| RS2481652194 |
SGCD
|
Health Risk |
Likely pathogenic |
Dilated cardiomyopathy 1L, Dilated cardiomyopathy 1L |
| RS2481653253 |
SGCD
|
Health Risk |
Pathogenic |
Autosomal recessive limb-girdle muscular dystrophy type 2F, Autosomal recessive limb-girdle muscular dystrophy type 2F |
| RS2481653983 |
SGCD
|
Health Risk |
Pathogenic |
Autosomal recessive limb-girdle muscular dystrophy type 2F, Autosomal recessive limb-girdle muscular dystrophy type 2F |
| RS2481656285 |
H4C3
|
Health Risk |
Likely pathogenic |
— |
| RS2481656826 |
H4C3
|
Health Risk |
Likely pathogenic |
H4C3-related disorder, H4C3-related disorder |
| RS2481725889 |
ZFP57
|
Health Risk |
Likely pathogenic |
— |
| RS2481741286 |
MLIP
|
Health Risk |
Pathogenic |
Myopathy with myalgia, increased serum creatine kinase |
| RS2481742586 |
MLIP
|
Health Risk |
Pathogenic |
Myopathy with myalgia, increased serum creatine kinase |
| RS2481766143 |
PHIP
|
Health Risk |
Pathogenic |
Inborn genetic diseases, Inborn genetic diseases |
| RS2481766764 |
PHIP
|
Health Risk |
Likely pathogenic |
PHIP-related behavioral problems-intellectual disability-obesity-dysmorphic features syndrome, PHIP-related behavioral problems-intellectual disability-obesity-dysmorphic features syndrome |
| RS2481797579 |
PHIP
|
Health Risk |
Pathogenic |
PHIP-related behavioral problems-intellectual disability-obesity-dysmorphic features syndrome, PHIP-related behavioral problems-intellectual disability-obesity-dysmorphic features syndrome |
| RS2481809653 |
NME5
|
Health Risk |
Pathogenic |
Ciliary dyskinesia, primary |
| RS2481817652 |
MAP3K7
|
Health Risk |
Conflicting classifications of pathogenicity |
— |
| RS2481822388 |
MAP3K7
|
Health Risk |
Conflicting classifications of pathogenicity |
Cardiospondylocarpofacial syndrome, Cardiospondylocarpofacial syndrome |
| RS2481832989 |
PHIP
|
Health Risk |
Pathogenic |
— |
| RS2481833141 |
PHIP
|
Health Risk |
Pathogenic |
PHIP-related behavioral problems-intellectual disability-obesity-dysmorphic features syndrome, Inborn genetic diseases |
| RS2481866114 |
PHIP
|
Health Risk |
Pathogenic |
PHIP-related behavioral problems-intellectual disability-obesity-dysmorphic features syndrome, PHIP-related behavioral problems-intellectual disability-obesity-dysmorphic features syndrome |
| RS2481866319 |
PHIP
|
Health Risk |
Pathogenic |
— |
| RS2481878430 |
PHIP
|
Health Risk |
Pathogenic |
PHIP-related behavioral problems-intellectual disability-obesity-dysmorphic features syndrome, PHIP-related behavioral problems-intellectual disability-obesity-dysmorphic features syndrome |
| RS2481878453 |
PHIP
|
Health Risk |
Likely pathogenic |
PHIP-related behavioral problems-intellectual disability-obesity-dysmorphic features syndrome, PHIP-related behavioral problems-intellectual disability-obesity-dysmorphic features syndrome |
| RS2481883298 |
BCKDHB
|
Health Risk |
Likely pathogenic |
Maple syrup urine disease, Maple syrup urine disease |
| RS2481884229 |
BCKDHB
|
Health Risk |
Likely pathogenic |
— |
| RS2481892793 |
PHIP
|
Health Risk |
Likely pathogenic |
— |
| RS2481897981 |
PHIP
|
Health Risk |
Likely pathogenic |
PHIP-related behavioral problems-intellectual disability-obesity-dysmorphic features syndrome, PHIP-related behavioral problems-intellectual disability-obesity-dysmorphic features syndrome |
| RS2481898172 |
BCKDHB
|
Health Risk |
Pathogenic |
Maple syrup urine disease, Maple syrup urine disease |
| RS2481898452 |
PHIP
|
Health Risk |
Likely pathogenic |
PHIP-related behavioral problems-intellectual disability-obesity-dysmorphic features syndrome, PHIP-related behavioral problems-intellectual disability-obesity-dysmorphic features syndrome |
| RS2481898824 |
BCKDHB
|
Health Risk |
Pathogenic/Likely pathogenic |
Maple syrup urine disease, Maple syrup urine disease type 1A |
| RS2481899561 |
BCKDHB
|
Health Risk |
Likely pathogenic |
Maple syrup urine disease, Maple syrup urine disease |
| RS2481900030 |
BCKDHB
|
Health Risk |
Pathogenic/Likely pathogenic |
Maple syrup urine disease, Maple syrup urine disease |
| RS2481900188 |
BCKDHB
|
Health Risk |
Pathogenic |
Maple syrup urine disease, Maple syrup urine disease |
| RS2481901220 |
BCKDHB
|
Health Risk |
Likely pathogenic |
Maple syrup urine disease, Maple syrup urine disease |
| RS2481919576 |
BCKDHB
|
Health Risk |
Likely pathogenic |
Maple syrup urine disease, Maple syrup urine disease |
| RS2481919877 |
BCKDHB
|
Health Risk |
Pathogenic |
Maple syrup urine disease, Maple syrup urine disease type 1A |
| RS2481920373 |
BCKDHB
|
Health Risk |
Likely pathogenic |
Maple syrup urine disease, Maple syrup urine disease |
| RS2481921012 |
BCKDHB
|
Health Risk |
Pathogenic |
Maple syrup urine disease, Maple syrup urine disease |
| RS2481921493 |
BCKDHB
|
Health Risk |
Likely pathogenic |
Maple syrup urine disease, Maple syrup urine disease |
| RS2481934703 |
RFX6
|
Health Risk |
Pathogenic |
— |
| RS2481937153 |
RFX6
|
Health Risk |
Likely pathogenic |
RFX6-related disorder, RFX6-related disorder |
| RS2481946427 |
RFX6
|
Health Risk |
Likely pathogenic |
RFX6-related disorder, RFX6-related disorder |
| RS2481953351 |
MLIP
|
Health Risk |
Pathogenic |
Myopathy with myalgia, increased serum creatine kinase |
| RS2481953475 |
MLIP
|
Health Risk |
Likely pathogenic |
MLIP-related disorder, MLIP-related disorder |
| RS2481960127 |
RFX6
|
Health Risk |
Pathogenic |
— |
| RS2481962808 |
PHIP
|
Health Risk |
Likely pathogenic |
PHIP-related disorder, PHIP-related disorder |
| RS2481963256 |
PHIP
|
Health Risk |
Pathogenic |
PHIP-related disorder, PHIP-related disorder |
| RS2481974697 |
PHIP
|
Health Risk |
Pathogenic |
— |
| RS2481981792 |
NUS1
|
Health Risk |
Likely pathogenic |
Congenital disorder of glycosylation, type IAA |
| RS2481982183 |
NUS1
|
Health Risk |
Likely pathogenic |
— |
| RS2481982381 |
NUS1
|
Health Risk |
Pathogenic |
Intellectual disability, autosomal dominant 55 |
| RS2481982600 |
NUS1
|
Health Risk |
Pathogenic |
Congenital disorder of glycosylation, type IAA |
| RS2481982643 |
NUS1
|
Health Risk |
Pathogenic |
Congenital disorder of glycosylation, type IAA |
| RS2481982674 |
NUS1
|
Health Risk |
Pathogenic |
Congenital disorder of glycosylation, type IAA |
| RS2481983096 |
NUS1
|
Health Risk |
Likely pathogenic |
Intellectual disability, autosomal dominant 55 |
| RS2481983107 |
NUS1
|
Health Risk |
Pathogenic |
Congenital disorder of glycosylation, type IAA |
| RS2481983161 |
NUS1
|
Health Risk |
Pathogenic |
Congenital disorder of glycosylation, type IAA |
| RS2481983215 |
NUS1
|
Health Risk |
Pathogenic |
Congenital disorder of glycosylation, type IAA |
| RS2481983597 |
NUS1
|
Health Risk |
Likely pathogenic |
Congenital disorder of glycosylation, type IAA |
| RS2481983720 |
NUS1
|
Health Risk |
Pathogenic |
Intellectual disability, autosomal dominant 55 |
| RS2481983841 |
NUS1
|
Health Risk |
Pathogenic |
Congenital disorder of glycosylation, type IAA |
| RS2481983883 |
NUS1
|
Health Risk |
Pathogenic |
Congenital disorder of glycosylation, type IAA |
| RS2481983903 |
NUS1
|
Health Risk |
Likely pathogenic |
NUS1-related disorder, NUS1-related disorder |
| RS2481983991 |
NUS1
|
Health Risk |
Likely pathogenic |
Intellectual disability, autosomal dominant 55 |
| RS2481984001 |
NUS1
|
Health Risk |
Pathogenic |
Congenital disorder of glycosylation, type IAA |
| RS2481999708 |
SEC63
|
Health Risk |
Likely pathogenic |
SEC63-related disorder, SEC63-related disorder |
| RS2482006049 |
PHIP
|
Health Risk |
Pathogenic |
PHIP-related behavioral problems-intellectual disability-obesity-dysmorphic features syndrome, PHIP-related behavioral problems-intellectual disability-obesity-dysmorphic features syndrome |
| RS2482006630 |
PHIP
|
Health Risk |
Likely pathogenic |
PHIP-related behavioral problems-intellectual disability-obesity-dysmorphic features syndrome, PHIP-related behavioral problems-intellectual disability-obesity-dysmorphic features syndrome |